Inherited thrombophilic risk factors in Serbian breast cancer patients

Abstract

Breast cancer is the leading cause of cancer-related death among women. An increased burden of thrombotic events among breast cancer patients, leading to higher mortality and morbidity rates, is well established. There are a number of genetic risk factors associated with thrombosis, but their contribution to thrombotic tendencies in patients with cancer is not completely elucidated. We aimed to investigate possible role of FV Leiden, FII G20210A, MTHFR C677T and PAI-1 4G/5G gene variants in etiopathology of breast cancer and accompanying thrombosis in cohort of Serbian patients. Our study included 316 subject divided in three groups: breast cancer patients with (97) or without (99) accompanying thrombosis and healthy control group (120). According to our results, the prevalence for all four prothrombotic gene variants were similar in cancer patients with and without thrombosis and no statistically significant difference was observed between these groups. We detected lower frequency of MTHFR 677TT genotype in breast cancer patients when compared to control group (P=0.014; OR=0.145 (95%CI 0.031-0.679)), 464

The Contribution of Inherited Thrombophilia to Venous Thromboembolism in Cancer Patients

“…Another study 28 from Serbia compared the frequencies of FVL, PT G20210A, MTHFR C677T and PAI-1 4G/5G, in 316 patients, 97 with breast cancer and VTE, 99 with breast cancer but no VTE and a healthy control group of 120 patients. Concerning patients with breast cancer, FVL was present in 14 patients with VTE (12 heterozygous, 2 homozygous) and 7 in the group with no VTE (6 heterozygous and 1 homozygous).…”